A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia
β Scribed by Gopalan Sethuraman; Cindy C. Taylor; Mark Enerson; Eduardo Dunayevich
- Book ID
- 119362503
- Publisher
- Elsevier Science
- Year
- 2005
- Tongue
- English
- Weight
- 80 KB
- Volume
- 79
- Category
- Article
- ISSN
- 0920-9964
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Metabolic changes were examined in patients with schizophrenia during treatment with either oral olanzapine or olanzapine longβacting injection (LAI). Data were collected from patients who had been stabilized on oral olanzapine (10, 15, or 20βmg/day) for β₯4βweeks and then randomized to either contin
Background Following an earlier study in which elderly patients with schizophrenia had their typical antipsychotic medication changed to olanzapine or risperidone, the 61 patients were followed for up to a further six months to see if either treatment was superior in terms of efficacy or side effect